Vinge advises EQT in connection with the acquisition of leading global pest control specialist Anticimex which becomes the first investment of EQT’s new purpose-driven strategy with longer-term investments and impact at its core.

Anticimex is a modern service company working with pest control, food safety, damp control, house inspections and fire protection. Anticimex has since 1934 developed from being a Swedish family business to an international company with over 4,500 employees in 17 countries. The transaction, where the selling party is the EQT VI fund, has an enterprise value of SEK 60 billion and the investment is made together with several long-term investors, such as Melker Schörling AB (MSAB), who will be the second largest shareholder, GIC, AMF, Interogo Holding Long-Term Equity and Alecta.

Vinge’s team consists of Christina Kokko and Peter Sundgren together with Maria Dahlin Kolvik, Ellinor Wargenbrant, Manne Bergström and Nando Basic (M&A/Corporate), Louise Brorsson Salomon, Seyran Sahin, Karl-Gustaw Tobola and Axel Jansson (Banking and Finance), Viveka Classon, Paulina Malmberg and David Lundahl (Corporate Insurance), Emma Stuart-Beck, Caroline Krassén and Elias Bohlin (Financial Services), Sofia Bergenstråhle (IPR), Isabell Nielsen (Commercial Agreements), Elin Broman (Employment), Lina Österberg and Ulf Pyk (Real Estate and Environment), Mika Jordan (IT), Nicklas Thorgerzon (GDPR) and Jessica Öijer (VDR). Partner Marcus Glader together with Emma Johansson and Johan Wahlbom advice in relation to merger filing.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025